| Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery |
Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous competence and maintaining clinical benefits Company has submitted PMA application for the VenoValve to the U.S. Food and Drug Administration (FDA) with a decision anticipated in the second half of 2025 IRVINE, CA / ACCESS Newswire / May 13, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that its manuscript titled, " Three-Year Outcomes of Surgical Implantation of a Novel Bioprosthetic Valve for the Treatment of Deep Venous Reflux 1," has been published in the in the peer-reviewed journal, Annals of Vascular Surgery. The VenoValve was surgically implanted in the femoral vein of eleven subjects with active or healed venous ulcers (CEAP classifications C5-C6). |
accessnewswire.com |
2025-05-13 12:45:00 |
Czytaj oryginał (ang.) |
| Zomedica Launches Groundbreaking Equine Asthma Clinical Registry Featuring PulseVet(R) Shock Wave Therapy |
Innovative Registry Harnesses Shock Wave Therapy to Advance Non-Drug Equine Asthma Treatment and Drive Evidence-Based Veterinary Care ANN ARBOR, MI / ACCESS Newswire / May 13, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the launch of the Equine Asthma Clinical Registry. This pioneering program leverages PulseVet® shock wave therapy to offer a non-invasive, drug-free treatment alternative for horses suffering from asthma. |
accessnewswire.com |
2025-05-13 10:30:00 |
Czytaj oryginał (ang.) |
| Launch of 60-Count Sleep Gummies into the Middle Eastern Markets Drives Further Growth of Delivra Health Brands' Dream Water(R) Brand |
Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods company uniquely positioned in the health and wellness sector, is pleased to announce that its Kuwait-based Dream Water® brand distributor is launching the Company's new 60-Count Sleep Gummies in Middle Eastern markets. The Company's 60-Count Sleep Gummies are expected to be available in the distributor's local markets by July 2025. |
newsfilecorp.com |
2025-05-08 21:05:00 |
Czytaj oryginał (ang.) |
| Edge Total Intelligence Recognized in the Gartner(R) Hype Cycle for Power and Utility Industry IT, 2024 |
$32B Global IT Services Analyst, Gartner (IT), Provides Guidance on Digital Twins Use Cases Arlington, Virginia--(Newsfile Corp. - May 8, 2025) - Edge Total Intelligence Inc. (TSXV: CTRL) (OTCQB: UNFYF) (FSE: Q5I) ("edgeTI", "Company"), a leading provider of real-time digital twin software, announces the Company was Recognized by Gartner® (NYSE: IT) in its Gartner Hype Cycle™ for Power and Utility IT, 2024 as a Sample Vendor in the Digital Twins category. The report states, "To ensure the continued provision of affordable and sustainable services, power and utilities companies must transform with digital technology. |
newsfilecorp.com |
2025-05-08 07:01:00 |
Czytaj oryginał (ang.) |
| Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization |
New analysis suggests efficacy of Xifaxan to mitigate OHE rehospitalizations irrespective of treatment history LAVAL, QC / ACCESS Newswire / May 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced new data showing that people hospitalized due to overt hepatic encephalopathy (OHE) had a reduced risk of OHE-related rehospitalization within 30 days if treated with Xifaxan® (rifaximin) following hospital discharge regardless of prior treatment. These findings, based on a claims-based analysis, will be presented today at Digestive Disease Week® (DDW) 2025 in San Diego, CA. |
accessnewswire.com |
2025-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| Ryder Declares Quarterly Cash Dividend |
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--The Board of Directors of Ryder System, Inc. (NYSE: R) declared a regular quarterly cash dividend of $0.81 per share of common stock to be paid on June 20, 2025, to shareholders of record on May 19, 2025. This is Ryder's 195th consecutive quarterly cash dividend – marking more than 48 years of uninterrupted dividend payments. About Ryder System, Inc. Ryder System, Inc. (NYSE: R) is a fully integrated port-to-door logistics and transportation company. It provides supply c. |
businesswire.com |
2025-05-02 20:30:00 |
Czytaj oryginał (ang.) |
| Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System |
A Long-Awaited Advancement in Non-Invasive Radiofrequency Skin Tightening Is Now Approved for the Canadian Market LAVAL, QC / ACCESS Newswire / April 29, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its aesthetic business, Solta Medical, announced today that Health Canada has granted medical device license clearance for Thermage® FLX, the latest generation of the globally-recognized Thermage® system for non-invasive skin tightening and contouring. "The clearance of Thermage FLX in Canada is a positive development for our company and important for the continued growth of our aesthetic business", said Thomas J. |
accessnewswire.com |
2025-04-29 12:00:00 |
Czytaj oryginał (ang.) |
| Fashion to Fine Wines & Spirits: Ryder Customers Share “Stories from the Supply Chain” in National TV Ad Campaign |
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder launches national TV ad campaign showcasing real businesses navigating logistics challenges in an ever-shifting supply chain environment. |
businesswire.com |
2025-04-28 10:55:00 |
Czytaj oryginał (ang.) |
| Ryder Q1 Earnings Surpass Estimates, Improve Year Over Year |
R's first-quarter 2025 revenues benefit from the prior-year acquisition and contractual revenue growth in Supply Chain Solutions and Fleet Management Solutions. |
zacks.com |
2025-04-25 18:05:33 |
Czytaj oryginał (ang.) |
| Ryder System, Inc. (R) Q1 2025 Earnings Call Transcript |
Ryder System, Inc. (NYSE:R ) Q1 2025 Earnings Conference Call April 23, 2025 11:00 AM ET Company Participants Calene Candela - Vice President, Investor Relations Robert Sanchez - Chairman and Chief Executive Officer Cristina Gallo-Aquino - Executive Vice President and Chief Financial Officer John Diez - President and Chief Operating Officer Tom Havens - President, Fleet Management Solutions Steve Sensing - President, Supply Chain Solutions and Dedicated Transportation Solutions Conference Call Participants Jordan Alliger - Goldman Sachs Christyne McGarvey - Morgan Stanley Jeff Kauffman - Vertical Research Partners Scott Group - Wolfe Research Reed Seay - Stephens Inc. Brian Ossenbeck - JPMorgan Harrison Bauer - Susquehanna Operator Good morning, and welcome to the Ryder System First Quarter 2025 Earnings Release Conference Call. All lines are in listen-only mode, until after the presentation. |
seekingalpha.com |
2025-04-23 20:20:08 |
Czytaj oryginał (ang.) |
| Ryder (R) Reports Q1 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Ryder (R) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-04-23 14:35:46 |
Czytaj oryginał (ang.) |
| Ryder (R) Q1 Earnings Top Estimates |
Ryder (R) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.40 per share. This compares to earnings of $2.14 per share a year ago. |
zacks.com |
2025-04-23 13:05:38 |
Czytaj oryginał (ang.) |
| Ryder Completes $1.6 Billion Corporate Revolving Credit Facility |
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) announces that it has established a new, upsized $1.6 billion five-year corporate revolving credit facility, which includes 11 global institutions and will expire on April 22, 2030. This replaces Ryder's current corporate credit facility and provides $200 million of additional credit capacity. “Execution of this new, upsized credit facility further solidifies Ryder's strong liquidity position for the next five years,” says Ryder Chief Financi. |
businesswire.com |
2025-04-23 11:00:00 |
Czytaj oryginał (ang.) |
| Ryder Reports First Quarter 2025 Results |
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) reported results for the three months ended March 31 as follows: Earnings Before Taxes Earnings Diluted Earnings Per Share (In millions, except EPS) 2025 2024 2025 2024 2025 2024 Continuing operations (GAAP) $ 134 114 $ 98 85 $ 2.29 1.89 Comparable (non-GAAP) $ 142 129 $ 106 96 $ 2.46 2.14 Total and operating revenue for the three months ended March 31 were. |
businesswire.com |
2025-04-23 10:55:00 |
Czytaj oryginał (ang.) |
| Ryder (R) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates |
Get a deeper insight into the potential performance of Ryder (R) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. |
zacks.com |
2025-04-21 14:20:50 |
Czytaj oryginał (ang.) |
| MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense |
HALIFAX, NS / ACCESS Newswire / April 17, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as the Veterans Health Administration (VHA), the Military Health System (MHS), and the Indian Health Service (IHS). Lovell Government Services will serve as MedMira's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve these customers through federal contracting systems. |
accessnewswire.com |
2025-04-17 10:00:00 |
Czytaj oryginał (ang.) |
| Theralase(R) Closes Non-Brokered Private Placement |
Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units"). On closing, the Corporation issued an aggregate of 1,995,829 Units at a price of $CAN 0.21 per Unit for aggregate gross proceeds of $CAN 419,124. |
newsfilecorp.com |
2025-04-14 20:22:00 |
Czytaj oryginał (ang.) |
| Ryder Named Among “America's Most Innovative Companies” in 2025 by Fortune |
MIAMI--(BUSINESS WIRE)--As the transportation and logistics industry continues to evolve, Ryder System, Inc. (NYSE: R) remains at the forefront of innovation, developing leading-edge solutions that enhance efficiency and operational excellence. In recognition of these efforts, Ryder has been named to the Fortune list of “America's Most Innovative Companies” in 2025. “To fully optimize supply chains and transportation networks, we continue to build on the $1.7 billion in strategic investments we. |
businesswire.com |
2025-04-09 10:55:00 |
Czytaj oryginał (ang.) |
| EdgeTI Recognized in the Gartner(R) Hype Cycle for Managing Operational Technology, 2024 |
$32B Global IT Services Analyst, Gartner(R) (IT), Continues to Focus on Functional Use Cases for Digital Twins Arlington, Virginia--(Newsfile Corp. - April 9, 2025) - Edge Total Intelligence Inc. (TSXV: CTRL) (OTCQB: UNFYF) (FSE: Q5i) ("edgeTI", "Company"), a leading provider of real-time digital twin software, announces the Company was Recognized in the Gartner® Hype Cycle™ for Managing Operational Technology, 2024 as a Sample Vendor in the Digital Twins category. The report states, "Operational technology (OT) is hardware and software that detects — or causes — a change in physical processes or events through the direct monitoring and/or control of physical devices, typically industrial equipment. |
newsfilecorp.com |
2025-04-09 07:01:00 |
Czytaj oryginał (ang.) |
| Telenet launches cutting-edge entertainment marketplace, powered by the Digital Vending Machine(R) from Bango |
Telenet customers enjoy effortless access to the best entertainment subscription bundles - all in one place Telenet customers enjoy effortless access to the best entertainment subscription bundles - all in one place |
globenewswire.com |
2025-04-08 08:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Investors Should Give Ryder System Stock a Miss Now |
Weak freight market conditions and elevated operating expenses are severely hurting Ryder's prospects. |
zacks.com |
2025-02-26 11:36:09 |
Czytaj oryginał (ang.) |
| Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma |
Rutherrin(R), when combined with a common diabetic drug and radiation, was able to effectively destroy Non-Hodgkin's Lymphoma in an animal model. Toronto, Ontario--(Newsfile Corp. - February 25, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that Rutherrin® has demonstrated an ability to destroy Non-Hodgkin's Lymphoma ("NHL") in an animal model, when combined with Metformin (a common diabetes drug) and radiation. |
newsfilecorp.com |
2025-02-25 18:15:00 |
Czytaj oryginał (ang.) |
| Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder |
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL) announced today that the supplemental New Drug Application (sNDA) for UZEDY extended-release injectable suspension for the maintenance treatment of BP-I in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA). |
globenewswire.com |
2025-02-25 18:00:00 |
Czytaj oryginał (ang.) |
| GMG Unveils G(R) Lubricant Engine Performance Testing Results: A Transformative Graphene Energy Saving Solution for the Multi Trillion Dollar Global Liquid Fuel Industry |
Brisbane, Queensland, Australia--(Newsfile Corp. - February 24, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce the results of the multi-year performance testing of G® Lubricant, a transformative graphene liquid concentrate additive designed to enhance the performance of diesel and gasoline (petrol) engines. |
newsfilecorp.com |
2025-02-24 10:39:00 |
Czytaj oryginał (ang.) |
| Ryder Leaders Reach Rock-Star Status in Food Logistics |
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder sweeps the 2025 Rock Stars of the Supply Chain awards by Food Logistics with three leaders from its consumer-packaged goods (CPG) business. |
businesswire.com |
2025-02-20 08:55:00 |
Czytaj oryginał (ang.) |
| One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum |
One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators. PMA application for the VenoValve submitted in November 2024, with an FDA decision expected in the second half of 2025. |
accessnewswire.com |
2025-02-19 10:45:00 |
Czytaj oryginał (ang.) |
| Bob Gold & Associates Named Agency of Record for the Largest Broadband Show in the Americas, SCTE TechExpo25 |
LOS ANGELES--(BUSINESS WIRE)-- #BobGoldPR--SCTE TechExpo25, the largest broadband event of its kind, names Bob Gold & Associates as its Agency of Record to drive industry engagement. |
businesswire.com |
2025-02-18 14:00:00 |
Czytaj oryginał (ang.) |
| CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators |
CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of the broadest intellectual property portfolios in mRNA technology TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / February 18, 2025 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its recognition as a Top 100 Global Innovator in the Innovation Momentum 2025 report by LexisNexis®. |
accessnewswire.com |
2025-02-18 09:15:00 |
Czytaj oryginał (ang.) |
| Fortune Names Ryder Among World's Most Admired Companies in 2025 |
MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) announces its recognition by Fortune magazine as one of the World's Most Admired Companies for 2025. This is the 13th consecutive year Ryder has been recognized, further solidifying its reputation for excellence in the trucking, transportation, and logistics category. “There's a reason we consistently earn top marks on Fortune's corporate reputation report card for attributes like workforce development, innovation, and product excellence,” sa. |
businesswire.com |
2025-02-18 08:55:00 |
Czytaj oryginał (ang.) |
| Ryder Q4 Earnings Surpass Estimates, Improves Year Over Year |
R's fourth-quarter 2024 results reflect higher earnings across all business segments. |
zacks.com |
2025-02-14 12:15:31 |
Czytaj oryginał (ang.) |
| CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes |
This Press Release updates numerical list in reference section Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ACCESS Newswire / February 13, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the previous University of Manitoba research has now been validated, proving that RuvidarTM is safe and effective in the inactivation of Herpes Simplex Virus, Type 1 ("HSV-1") in an animal model. |
accessnewswire.com |
2025-02-13 14:30:00 |
Czytaj oryginał (ang.) |
| Ryder Included in Forbes' Canada's Best Employers List for 2025 |
MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) celebrates the recognition by Forbes as one of Canada's Best Employers in 2025. As a top supply chain and transportation company in the logistics business, this 2025 recognition marks the first year Ryder has been included in the Canada's Best Employers List by Forbes. This prestigious award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider. Forbes and Statista selected 300 of Canad. |
businesswire.com |
2025-02-13 08:55:00 |
Czytaj oryginał (ang.) |
| Theralase(R) Demonstrates Effective Treatment of Herpes |
Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ACCESS Newswire / February 12, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the previous University of Manitoba research has now been validated, proving that RuvidarTM is safe and effective in the inactivation of Herpes Simplex Virus, Type 1 ("HSV-1") in an animal model. |
accessnewswire.com |
2025-02-12 18:15:00 |
Czytaj oryginał (ang.) |
| Ryder System, Inc. (R) Q4 2024 Earnings Call Transcript |
Ryder System, Inc. (NYSE:R ) Q4 2024 Earnings Conference Call February 12, 2025 11:00 AM ET Company Participants Calene Candela - Vice President, Investor Relations Robert Sanchez - Chairman and Chief Executive Officer Cristina Gallo-Aquino - Executive Vice President and Chief Financial Officer John Diez - President and Chief Operating Officer Tom Havens - President, Fleet Management Solutions Steve Sensing - President, Supply Chain Solutions and Dedicated Transportation Solutions Conference Call Participants Christyne McGarvey - Morgan Stanley Jeff Kauffman - Vertical Research Partners Jordan Alliger - Goldman Sachs Daniel Imbro - Stephens Harrison Bauer - Susquehanna Operator Good morning and welcome to the Ryder System Fourth Quarter 2024 Earnings Release Conference Call. All lines are in a listen-only mode until after the presentation. |
seekingalpha.com |
2025-02-12 16:19:42 |
Czytaj oryginał (ang.) |
| Ryder (R) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates |
Although the revenue and EPS for Ryder (R) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-12 13:01:04 |
Czytaj oryginał (ang.) |
| Caldwell and Bennett Jones Announce the 2024 Recipient of Canada's Outstanding CEO of the Year(R) |
TORONTO, ON / ACCESS Newswire / February 12, 2025 / Caldwell (TSX:CWL)(OTCQX:CWLPF) and Bennett Jones today announced Canada's Outstanding CEO of the Year® for 2024 is WSP Global's Alexandre L'Heureux. Canada's Outstanding CEO of the Year® for 2024 is WSP Global's Alexandre L'Heureux. |
accessnewswire.com |
2025-02-12 11:30:00 |
Czytaj oryginał (ang.) |
| Ryder (R) Tops Q4 Earnings Estimates |
Ryder (R) came out with quarterly earnings of $3.45 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $2.95 per share a year ago. |
zacks.com |
2025-02-12 11:06:08 |
Czytaj oryginał (ang.) |
| Ryder Reports Fourth Quarter 2024 Results and Provides 2025 Outlook |
MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) reported results for the three months ended December 31 as follows: (In millions, except EPS) Earnings Before Taxes Earnings Diluted Earnings Per Share 2024 2023 2024 2023 2024 2023 Continuing operations (GAAP) $ 181 160 $ 135 124 $ 3.11 2.74 Comparable (non-GAAP) $ 199 172 $ 150 134 $ 3.45 2.95 Total and operating revenue for the three months ended December 31 were as follows: (In millions) Total. |
businesswire.com |
2025-02-12 08:55:00 |
Czytaj oryginał (ang.) |
| R's Q4 Earnings Coming Up: What's in the Offing for the Stock? |
R's fourth-quarter 2024 revenues are expected to have benefited from strength across all segments. |
zacks.com |
2025-02-11 12:05:18 |
Czytaj oryginał (ang.) |
| EdgeTI Recognized in the 2024 Gartner(R) Emerging Tech: Revenue Opportunity Projection of Simulation Digital Twins |
Arlington, Virginia--(Newsfile Corp. - February 11, 2025) - Edge Total Intelligence Inc. (TSXV: CTRL) (OTCQB: UNFYF) (FSE: Q5i) ("edgeTI", "Company"), a leading provider of real-time digital twin software, announces the Company was Recognized in the 2024 Gartner® Emerging Tech: Revenue Opportunity Projection of Simulation Digital Twins as one of the Example vendors in Simulation Digital Twin of a Person (SDToP). The report states, "Simulation digital twins (SDTs) are an advanced version of traditional digital twin solutions that provide such capability. |
newsfilecorp.com |
2025-02-11 05:01:00 |
Czytaj oryginał (ang.) |
| Here's Why Investors Should Give Ryder System Stock a Miss Now |
R is grappling with a downturn in freight market conditions, hurting its prospects. Escalated operating expenses are a major headwind. |
zacks.com |
2025-01-03 14:26:14 |
Czytaj oryginał (ang.) |
| Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R) |
Northvale, New Jersey--(Newsfile Corp. - December 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Vyvanse® (Lisdexamfetamine Disylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules. The product is indicated for the treatment of attention deficit hyperactivity disorder (ADHD). |
newsfilecorp.com |
2024-12-26 09:00:00 |
Czytaj oryginał (ang.) |
| MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV |
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo® Rapid TP/HIV Test (Multiplo® TP/HIV) to be rolled out across Canada, a critical point-of-care tool to address the health crises with HIV and syphilis in Canada. The single Reveal® TP (Syphilis) approval will follow soon after this more complex approval. |
accesswire.com |
2024-12-24 14:00:00 |
Czytaj oryginał (ang.) |
| Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone |
With the addition of these two new assay launches, Zomedica has added 8 new assays in the past 18 months to the rapidly growing TRUFORMA Platform ANN ARBOR, MI / ACCESSWIRE / December 23, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform. Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum. |
accesswire.com |
2024-12-23 08:30:00 |
Czytaj oryginał (ang.) |
| Dalrada Financial Corporation's Deposition Technology Makes Spectroptix(R) Available for Advance Ordering |
Deptec's plasma spectrometer is primed to play an integral role in the booming semiconductor manufacturing and thin-film sectors. SAN DIEGO, CA / ACCESSWIRE / December 17, 2024 / Dalrada Financial Corporation (OTC PINK:DFCO), "Dalrada," "the Company"), announced today that Spectroptix®, a proprietary advanced plasma spectrometer developed by its subsidiary, Deposition Technology ("Deptec,"), is now available for advance ordering. |
accesswire.com |
2024-12-17 10:00:00 |
Czytaj oryginał (ang.) |
| Ryder Names Chief Operating Officer and New Chief Financial Officer |
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder appoints industry and company veterans to top operations and financial roles, naming chief operating officer and new chief financial officer. |
businesswire.com |
2024-12-16 18:35:00 |
Czytaj oryginał (ang.) |
| Edge Total Intelligence Recognized in the 2024 Gartner(R) Market Guide for Digital Twin of an Organization Platforms |
Arlington, Virginia--(Newsfile Corp. - December 12, 2024) - Edge Total Intelligence Inc. (TSXV: CTRL) (OTCQB: UNFYF) (FSE: Q5I) ("edgeTI", "Company"), a leading provider of real-time Digital Operations software that create Digital Twins that enable AI and other digital innovations, announced that it was recognized as a Representative Vendor in the newly published Gartner® Market Guide for Digital Twin of an Organization Platforms" report. edgeTI™ believes that the Company was identified for its focus on the operational excellence use case, followed by the manufacturing/supply chain and business performance management use cases. |
newsfilecorp.com |
2024-12-12 05:01:00 |
Czytaj oryginał (ang.) |
| GMG's THERMAL-XR(R) Demonstrates Potential for Electronics Heat Sink Miniaturization and Efficiency |
Brisbane, Queensland, Australia--(Newsfile Corp. - December 11, 2024) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to provide a business update on the commercialisation progress of THERMAL-XR® Powered by GMG Graphene. |
newsfilecorp.com |
2024-12-11 10:15:00 |
Czytaj oryginał (ang.) |
| Neos S&P 500(R) High Income ETF Harnesses the Power of Options |
Neos S&P 500(R) High Income ETF BATS: SPYI is an interesting play on the S&P 500 benchmarked to the CBOE's S&P 500 Buy-Write index. The Buy-Write index tracks potential returns from an S&P 500-oriented covered call strategy, which is the SPYI's primary focus. |
marketbeat.com |
2024-12-11 08:55:04 |
Czytaj oryginał (ang.) |
| Protium Clean Energy Corp. Announces Appointment of John Ryder to Advisory Board |
Toronto, Ontario--(Newsfile Corp. - December 10, 2024) - Protium Clean Energy Corp. (CSE: GRUV) (FSE: G071), a leading resource company focused on clean energy and sustainable resource development, is pleased to announce that it has appointed John Ryder, P.Geo to its advisory board. Mr. Ryder has been engaged in mineral exploration worldwide for over 40 years exploring for a variety of commodities and gems as both a geologist and as management of public companies. |
newsfilecorp.com |
2024-12-10 10:19:00 |
Czytaj oryginał (ang.) |
| Theralase(R) Launches Three New Clinical Study Sites in USA |
Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of Theralase®'s bladder cancer treatment TORONTO, ON / ACCESSWIRE / December 9, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has launched three new US-based Clinical Study Sites ("CSSs") for its bladder cancer registrational clinical study; specifically: Associated Medical Professionals of NY (Syracuse, New York), Urology of Indiana (Greenwood, Indiana) and Central Ohio Urology Group (Gahanna, Ohio). The Principal Investigators (" PIs ") for the Theralase® clinical study at the new CSSs are as follows: Associated Medical Professionals of NY - Ilija Aleksic, MD Dr. Aleksic graduated summa cum laude from the University at Buffalo and went on to complete medical school at SUNY Upstate Medical University. |
accesswire.com |
2024-12-09 10:05:00 |
Czytaj oryginał (ang.) |
| Mace(R) Security International, Inc. Announces Completion of Going Private Merger with W Electric Intermediate Holdings, LLC |
CLEVELAND, OH / ACCESSWIRE / December 6, 2024 / Mace Security International (OTCQB:MACE) (the "Company") announces the completion of the merger (the "Merger") contemplated by the Agreement and Plan of Merger (the "Merger Agreement") dated October 12, 2024 by and among W Electric Intermediate Holdings, LLC, a Delaware limited liability company ("Parent"), Mace Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), the Company and a representative of the Company's stockholders (the "Stockholders' Representative"). Charles A. |
accesswire.com |
2024-12-06 19:15:00 |
Czytaj oryginał (ang.) |
| Mace(R) Security International, Inc. Announces Stockholder Approval of Merger with W Electric Intermediate Holdings, LLC |
CLEVELAND, OH / ACCESSWIRE / December 5, 2024 / Mace Security International (OTCQB:MACE) (the "Company) announces the results of the Special Meeting of its stockholders held on December 3, 2024. At the Special Meeting, the Company's stockholders voted in favor of all proposals, including the proposal to adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement") by and among W Electric Intermediate Holdings, LLC, a Delaware limited liability company (the "Parent"), Mace Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (the "Merger Sub"), Mace and a representative of the Company's stockholders (the "Stockholders' Representative"). |
accesswire.com |
2024-12-05 12:30:00 |
Czytaj oryginał (ang.) |
| Theralase(R) Launches New Clinical Study Site in Canada |
St. Joseph's Healthcare Hamilton is the latest Canadian clinical study site for clinical investigation of Theralase®'s Anti-Cancer Therapy for the treatment of bladder cancer TORONTO, ON / ACCESSWIRE / December 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has launched a new Clinical Study Site ("CSS") for its bladder cancer clinical study; specifically, St. Joseph's Healthcare Hamilton (Hamilton, Ontario, Canada). Theralase®'s lead drug, RuvidarTM (TLD-1433), activated by the TLC-3200 Medical Laser System ("TLC-3200") is currently under clinical investigation in Canada and the United States in a Phase II registration study for Bacillus Calmette-Guérin ("BCG")-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") with or without resected Ta / T1 papillary disease ("Study II"). |
accesswire.com |
2024-12-05 09:00:00 |
Czytaj oryginał (ang.) |
| New Highs for Dow Transports: Top 3 Stocks Driving the Surge |
The Dow Jones Transportation Average rose more than 8.4% in November to set a new high. Most components saw gains, with only two moving lower. |
marketbeat.com |
2024-12-04 10:30:19 |
Czytaj oryginał (ang.) |
| Ryder Sets New Giving Record With $1.150 Million Donation to United Way |
MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) announces the company's annual United Way workplace campaign contributions for 2024 total $1.150 million—setting a record in the company's more than 40-year history supporting United Way. The total 2024 donation includes employee donations and a contribution from the Ryder Charitable Foundation. This year's workplace giving campaign, themed “Providing essential help right HERE,” united Ryder employees across the U.S. through five days of virt. |
businesswire.com |
2024-12-03 08:55:00 |
Czytaj oryginał (ang.) |
| First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel) |
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that the first patient has been treated with TECELRA® (afamitresgene autoleucel). TECELRA is the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults. |
newsfilecorp.com |
2024-12-02 18:00:00 |
Czytaj oryginał (ang.) |
| Theralase(R) Release's 3Q2024 Financial Statements |
TORONTO, ON / ACCESSWIRE / November 27, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's unaudited condensed consolidated interim financial statements for the nine-month period ended September 30, 2024. (" Financial Statements "). |
accesswire.com |
2024-11-27 19:05:00 |
Czytaj oryginał (ang.) |
| Here's Why Investors Should Retain Ryder Stock Right Now |
R's robust initiatives toward sustainability are praiseworthy. Shareholder-friendly approach too bodes well for R. |
zacks.com |
2024-11-27 12:40:48 |
Czytaj oryginał (ang.) |
| Ryder CEO to Address Goldman Sachs Industrials & Materials Conference |
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) Chairman & CEO Robert Sanchez will present a company update at the Goldman Sachs Industrials & Materials Conference 2024. Who: Ryder System, Inc. Chairman & CEO Robert Sanchez What: Goldman Sachs Industrials & Materials Conference Where: New York, NY When: Wednesday, December 4, 2024 Time: 1:20 p.m. Eastern Standard Time Webcast: To access the live webcast, visit Ryder - Goldman Sachs Industrials & Materials Conf. |
businesswire.com |
2024-11-26 08:55:00 |
Czytaj oryginał (ang.) |